Close Menu

Sharon Klugewicz

Feb 12, 2019

Chembio said in a filing with the US Securities and Exchange Commission that Sharon Klugewicz is resigning as its senior vice president and chief quality and regulatory officer on Feb. 22.

More Like This

Jul 18, 2019

Tristan Orpin, Randy Armant, Richard Shippy, Sascha Drewlo

NIPT startup Cradle Genomics of San Diego announced its management team this week.

Tristan Orpin is the firm's CEO. Previously, he was chief commercial officer and executive VP of clinical genomics at Illumina. Prior to that, he held executive positions at Sequenom and at Bio-Rad Laboratories. Orpin has a BSc in genetics and biochemistry from the University of Melbourne.

Randy Armant is a cofounder and the firm's VP of research. He is a professor of obstetrics and gynecology at Wayne State University. Armant holds a PhD in developmental biology and biochemistry from Virginia Tech.

Richard Shippy is a cofounder and the company's VP of commercial. Previously, he was the senior director of strategic product marketing in reproductive and genetic health at Illumina. Before that, he held management positions in clinical market development at Affymetrix and at GE Healthcare. Shippy holds an MSc in biochemistry from Northern Illinois University.

Sascha Drewlo is a cofounder and Cradle's VP of development. He holds a PhD in molecular and cell biology from the German Sport University Cologne and an MSc in microbiology and genetics from the University of Münster.

Jul 18, 2019

Kirk Wojno

OncoCell MDx, an immunogenomics company developing noninvasive molecular diagnostic assays, has named Kirk Wojno as chief medical officer. Wojno is former head of urologic pathology at the University of Michigan; at Ascension Health System; and AmeriPath, a division of Quest Diagnostics. He has more than 30 years in medical practice and most recently served as the chief of pathology and laboratory services and director of cinical research for the Comprehensive Urology practice in Royal Oak, Michigan.

Jul 17, 2019

J. Wallace Parce

Ontera, a Santa Cruz, California-based firm developing silicon-based nanopore diagnostics, has appointed J. Wallace Parce to its advisory board. He has cofounded and held senior positions at a number of life science technology companies including Nanosys, Caliper Technologies, and Molecular Devices. 

Parce was an associate professor at Wake Forest University's medical school and also received his doctorate from that university.

Jul 12, 2019

Paula Trzepacz

Todos Medical has appointed Paula Trzepacz chief medical officer of Breakthrough Diagnostics, which Todos is in the process of acquiring from Amarantus Bioscience Holding. She is a geriatric psychiatrist and neuropsychiatrist with expertise in the clinical development of therapeutics and diagnostics for Alzheimer's disease and other neurocognitive ailments. Trzepacz is a volunteer professor of psychiatry at Indiana University School of Medicine and an adjunct professor of psychiatry at Tufts University School of Medicine. She also was president of the Academy of Psychosomatic Medicine from 2004 to 2005 and president of the American Neuropsychiatric Association from 2009 to 2011. She is a fellow of both organizations.
Jul 12, 2019

Alexander Mackinnon

Alexander “Craig” Mackinnon has become the inaugural director of the Division of Genomics, Diagnostics, and Bioinformatics in the Department of Pathology at the University of Alabama at Birmingham School of Medicine. He will lead ongoing efforts to establish a Precision Diagnostic Laboratory at UAB. 

Mackinnon is a board-certified anatomical and molecular genetic pathologist. Previously, he was associate professor in the Department of Pathology at the Medical College of Wisconsin, where he directed the Clinical and Translational Research Laboratory, which developed multiple sequencing-based panels targeting variants in both DNA and RNA. 

Jul 10, 2019

Keng Hsu

Keng Hsu has stepped down from the board of Yourgene to improve the balance of executive and non-executive directors and to allow him to focus on business development in Asia. Yourgene plans to add non-executive directors to its board in the near future.

Jul 09, 2019

Christopher Thibodeau

OncoCell MDx has appointed Christopher Thibodeau as chief operating officer. Prior to OncoCell MDx, Thibodeau served as COO at MDxHealth. Before MDxHealth, he held various positions at Agendia, Numira Biosciences, LabCorp's US LABS, and Roche Diagnostics' Ventana Medical Systems 

Jul 03, 2019

Steven Averbuch

Steven Averbuch has joined Caris Life Sciences' scientific advisory board. Averbuch recently retired from the role of vice president and head of precision medicine in the translational medicine division of R&D at Bristol-Myers Squibb. During his tenure, Averbuch spearheaded the Pharmacodiagnostics Center of Excellence, which led to the application of BMS' precision medicine strategy across all therapeutic areas. Prior to this, Averbuch oversaw corporate-wide strategic initiatives for translational and targeted medicine at BMS. He also served as head of early global clinical research at the company. Averbuch also previously held leadership roles with Merck Research Laboratories and AstraZeneca, and held academic appointments at Mount Sinai School of Medicine and the US Public Health Service School of Medicine.

Jul 03, 2019

Jonathan Genzen

ARUP Laboratories appointed Jonathan Genzen as its chief operating officer effective July 1. Genzen has held a number of positions since starting at ARUP in January 2013. He served as its chemistry section chief and medical director for its automated core laboratory, laboratory automation, and Farmington clinical laboratory, among other responsibilities. Prior to joining ARUP, Genzen was a faculty member in the Department of Pathology and Laboratory Medicine at Weill Cornell Medical College.

Jul 02, 2019

Grace Colón

CareDx has appointed Grace Colón to its board of directors.  Colón currently served as president, CEO, and director of InCarda Therapeutics. She is also executive chairman of ProterixBIo and is on the board of Cocoon Biotech. Colón previously served on the boards of Paradigm Diagnostics and PerceptiMed. Colón has also served as a partner at New Science Ventures and held various leadership roles at Intrexon, Gilead Sciences, and Affymetrix. She will succeed Amy Abernethy on CareDx's board. 

Jul 01, 2019

David Rubin, Timothy Harris

David Rubin and Timothy Harris informed OpGen that they would be leaving the company's board, effective June 30. OpGen disclosed the resignations in a document filed with US Securities and Exchange Commission on July 1. Both had been on OpGen's board since 2015. The company said there had been no disagreement with Rubin or Harris leading to their resignations. 

Jul 01, 2019

Aamir Ali, Gary Falk, John Inadomi,

Cernostics has formed its medical advisory board, including Aamir Ali, Gary Falk, John Inadomi, Richard Lash, Nicholas Shaheen, and Sachin Wani. According to the firm, the members of board have been invovled in developing and publishing several BE and CE guidelines, participating in major BE clincal and research initiatives, and have served on the editorial boards of major gastroenterology journals. 

Ali is an associate director of research at Capital Digestic Care and consulting chief medical officer at Meridian Bioscience. Falk is a professor of medicine at the University of Pennsylvania Perelman School of Medicine and  the clinical co-director of the Esophagology and Swallowing Center. John Inadomi is the division head of gastroenterology at the University of Washington School of Medicine. Lash is president of R Lash MD Consulting and an associate clinical professor of Pathology at UT-Southwestern Medical Center. Shaheen is a professor of medicine at the University of North Carolina School of Medicine, as well as the chief of the gasteroenterology and hepatology center at UNC HealthCare. Wani is an associate professor of medicine, gastroenterology and medical director of the esophageal and gastric center at the University of Colorado School of Medicine. 

Jul 01, 2019

Keith Kennedy

Veracyte has appointed Keith Kennedy as chief operating officer. Prior to joining Veracyte, Kennedy served as executive leadership positions at MCG Capital, Arlington Capital Partners, and GE Capital over the past 20 years.

Jun 28, 2019

Eugene Durenard, Ted Murphy

Co-Diagnostics have appointed Eugene Durenard and Ted Murphy to its board of directors, and will serve on the board's compensation and corporate governance/nomination committees and audit committees as independent directors. The two new members will be replacing Frank Kiesnar, who resigned as director of the firm, and Edward Borkowski, who retired as a director of the firm.

Durenard has been founder and CEO of Hyperbolic Holdings since 2018, co-founder and chief innovation officer of Healthcare Impact Holdings since May 2018, co-founder and trustee of Healthcare Impact Foundation since 2017, co-founder of Global Better Health since December 2018, as well as advisor and managing director of the Stetson Family Office since September 2016.

Murphy serves on the board of directors of three Canadian publicly reporting companies, as well as a senior partner in a private investment firm since 1999.

Jun 27, 2019

Thomas West

Hologic announced that Thomas West, its diagnostics division president, resigned effective July 1. In a filing with the US Securities and Exchange Commission, the firm said he is leaving Hologic to assume the role of CEO at another publicly traded company.